Drug shortages, drug costs, the questionable quality of over-the-counter medicines: myriad issues have developed in pharmaceuticals in an era of enhanced regulatory efforts, rising healthcare costs and a global economy in which drug components are manufactured around the world. The new war on drugs is a policymaking battle in the legislative arena not over illicit back-alley dealing, but over cost, control and accessibility of the pills populating Americans' medicine cabinets.
Discover Drugs: Costs and Controls Content
FILTER BY DATEAll Time
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The Indian government has threatened legal action against the authors of a paper on Indian drug export quality. This unfortunate response, if it proceeds, will ultimately hurt India, not the authors.
Drug quality is poorer among Indian-labelled drugs purchased inside African countries than among those purchased inside India or middle-income countries. Substandard drugs, which contain insufficient amounts of the active ingredient, are the biggest driver of this quality difference.
The Indian government must curb the flow of low-quality medications from Indian drug manufacturers to foreign markets. These substandard medicines provide ineffective treatment, at best, and endanger global health, at worst.
In a new study, 10.9 percent of antibiotic and tuberculosis drug samples that claimed to be made in India and were sold around the globe failed a basic assessment of quality.
A year ago, the Food and Drug Administration quietly posted a public notice that it wanted to hire an independent lab to test a generic drug that it had already approved. FDA wanted to make sure the drug was safe and effective.
Drug counterfeits can have extreme health consequences on the consumer; drugs with the wrong active ingredients can cause poor health outcomes and can create resistance to medication.